Program
Alpelisib
Also written as “BYL719”, “alpelisib” and “BYL719 as film-coated (FC) whole tablets”.
Its studies are mostly in Breast Neoplasms · Squamous Cell Carcinoma of Head and Neck · Neoplasms · Ovarian Neoplasms · Lymphatic Abnormalities, led by 4 companies.
Drug pageAlpelisib: every studyAll 85 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 3310 open or running | phase 4since Nov 21, 2022 | Oct 6, 2010 | Jan 28, 2027phase 3 · NCT05038735 |
| Pfizerits history only | 20 open or running | phase 2since Oct 30, 2012 | Oct 6, 2011 | none ahead |
| Criterium | 11 open or running | phase 2since Dec 27, 2021 | Dec 27, 2021 | none ahead |
| Kura Oncologyits history only | 10 open or running | phase 2since Jul 27, 2021 | Jul 27, 2021 | none ahead |
Also a collaborator on its studies: ImmunityBio.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Criterium only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 27, 2021First study: phase 2 study in HER2-positive Metastatic Breast CancerFirst studyNCT05230810 · 40 enrolled · United States
TargetBeta
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule
Other programs on PIK3CA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| inavolisibrule | Hoffmann-La Roche | phase 3 | 20 |
| tersolisib | Eli Lilly | phase 3 | 10 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K-alpha Inhibitor JS105rule | risen-suzhou-pharma-tech-co-ltd | phase 3 | 1 |
| serabelisibrule | Takeda | phase 2 | 11 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| risovalisibrule | Haihe Biopharma | phase 2 | 4 |
| zovegalisibrule | relay-therapeutics-inc | phase 2 | 2 |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | pikavation-therapeutics-inc | phase 2 | 1 |
| Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636rule | ensem-therapeutics | phase 2 | 1 |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 1 |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | cogent-biosciences-inc | phase 1 | 1 |
Studies
The one study Criterium leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05230810HER2-positive Metastatic Breast Cancer · United States | 2 | Active, not recruiting | Mar 30, 2026 | 40 |
How it is read
Names in the registry
- “Alpelisib”, 18 entries
- “BYL719”, 13 entries
- “alpelisib”, 3 entries
- “BYL719 as film-coated (FC) whole tablets”, 1 entry
- “BYL719 as dispersible tablets (DT)”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 17 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
- Lymphatic Abnormalities, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.